The short answer
Native IGF-1 is 70 residues and binds IGF binding proteins with high affinity. LR3 is 83 residues and largely does not. A recombinant native IGF-1 is an approved medicine. Mecasermin, marketed as Increlex. LR3 is not that molecule and is approved nowhere.
Key facts
- Native IGF-1
- 70 residues, ~7.6 kDa
- IGF-1 LR3
- 83 residues
- Native IGFBP binding
- High affinity
- LR3 IGFBP binding
- Substantially reduced
- Approved native product
- Mecasermin (Increlex), subcutaneous
- Approved LR3 product
- None
The structural difference
Thirteen extra residues at the N-terminus and one substitution at position 3. That is the whole of it. The folded core and the three disulfide bonds are otherwise the native architecture. A modest change by residue count, aimed at one interaction.
The functional difference
Native IGF-1 in circulation is almost entirely sequestered by binding proteins. LR3 largely escapes that, which raises its free fraction substantially at the same total concentration. The receptor engagement is not different; the availability is.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
The regulatory difference, which is the important one
Mecasermin is recombinant human IGF-1 with an FDA-approved label, marketed as Increlex and administered subcutaneously. It has been used in severe primary IGF-1 deficiency. Petriczko and colleagues reported on this in 2019, and Denaite and colleagues described patient characteristics and treatment efficacy in Frontiers in Pediatrics in 2024. That is a licensed medicine with an indication and an evidence base.
And LR3 is not it
The approved product is native rhIGF-1. LR3 is an engineered analogue with different binding behaviour, no marketing authorisation anywhere, and no clinical development programme. The existence of an approved IGF-1 medicine does not extend to it in any respect, and conflating the two is the most consequential error available in this category.
Why the modification was not pursued clinically
The binding protein system is not merely an obstacle. It regulates a growth factor with receptors on every tissue. An analogue engineered to bypass that regulation removes a control mechanism rather than a nuisance. Its development context was cell culture, where controlled availability in a dish is the goal and systemic regulation is not a consideration.
Prohibited status applies to both
IGF-1 and its analogues appear on the WADA Prohibited List under class S2, prohibited at all times in and out of competition. That covers native and engineered forms alike.
Frequently asked questions
Is there an approved IGF-1 medicine?
Yes. Mecasermin, marketed as Increlex, is recombinant human IGF-1 administered subcutaneously. It is native rhIGF-1, not LR3.
Does that approval cover LR3?
No. LR3 is a different molecule with different binding behaviour and holds no marketing authorisation anywhere.
Why wasn't LR3 developed clinically?
Its modifications bypass a regulatory system rather than an obstacle. Its development context was cell culture, where systemic regulation is not a consideration.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- FDAFDA label: mecasermin (Increlex)accessdata.fda.gov
- PubMedPetriczko E et al., Treatment of severe primary IGF-1 deficiency using rhIGF-1. Endokrynol Pol 2019 (PMID 30351442)pubmed.ncbi.nlm.nih.gov
- PubMedDenaite D et al., Clinical characteristics and treatment efficacy in primary severe IGF-1 deficiency. Front Pediatr 2024 (PMID 39529965)pubmed.ncbi.nlm.nih.gov
- RefWADA Prohibited Listwada-ama.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- Why LR3 Exists: The Cell Culture ApplicationCultured cells secrete their own binding proteins, which sequester added IGF-1 unpredictably. An analogue that resists them gives consistent availability.
- IGF-1 LR3 Storage: A Folded Protein, Not a PeptideA folded protein can lose activity while remaining chemically intact. Why denaturation and adsorption matter more here than chemical degradation.
- How to Verify a Protein With No PubChem RecordIGF-1 is not in PubChem - proteins are indexed in UniProt instead. What that means for checking a certificate, and what a certificate should carry.
- IGF-1 LR3 and Anti-Doping StatusIGF-1 and its analogues sit in WADA class S2, prohibited in and out of competition. What that classification covers and why it is unconditional.
- IGF-1 LR3 Regulatory StatusNo marketing authorisation anywhere, though an approved native rhIGF-1 exists. Why that distinction is the important one in this category.